文献速递神经肿瘤

定义1型神经纤维瘤病小鼠视路胶质瘤发生的时间进程揭示减轻视网膜功能障碍的治疗窗

Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
PubMed 文献 · Neuro Oncol · 2017-01-01

研究在Nf1flox/mut GFAP-Cre(FMC)小鼠中按2至24周龄多个时间点观察视路胶质瘤发生过程,发现增殖升高最早出现于4周,微胶质激活与轴突损伤及视网膜神经节细胞凋亡出现在6周,视网膜神经节细胞丢失和视网膜神经纤维层变薄出现在9周,12周起给予洛伐他汀可阻止后续视网膜神经节细胞丢失和视网膜神经纤维层变薄,并建立光学相干断层扫描(OCT)作为视网膜神经节细胞丢失的准确生物标志物。

要点

  • FMC小鼠视路胶质瘤发生中增殖升高最早出现于4周龄,早于微胶质细胞增多和S100+胶质细胞增加。
  • 微胶质激活、轴突损伤和视网膜神经节细胞凋亡在6周龄出现,视网膜神经节细胞丢失和视网膜神经纤维层变薄在9周龄出现。
  • 12至16周龄给予洛伐他汀可阻止治疗后即刻及治疗结束后8周的进一步视网膜神经节细胞丢失和视网膜神经纤维层变薄。

核心结论

  • 通过明确视路胶质瘤发病相关的细胞和分子事件时间顺序,研究展示了神经保护干预和视力保存的关键时期,并建立OCT作为视网膜神经节细胞丢失的准确生物标志物。

研究设计与样本

  • 研究采用Nf1flox/mut GFAP-Cre(FMC)小鼠与年龄匹配的Nf1flox/flox(FF)对照,在2周至24周龄的设定间隔安乐死,测量视神经体积并对视神经/视网膜进行免疫组织化学分析,对麻醉小鼠行OCT,FMC小鼠在12至16周龄接受洛伐他汀治疗。

主要发现

  • 肿瘤发生中最早的事件是增殖持续升高(4周),随后出现持续微胶质细胞数量和S100+胶质细胞逐渐增加。
  • 微胶质激活表现为白细胞介素(IL)-1β表达增加和形态改变,与轴突损伤和视网膜神经节细胞凋亡同时出现(6周)。
  • 视网膜神经节细胞丢失和视网膜神经纤维层变薄随后出现(9周),由直接测量和活体OCT揭示。
  • 12周给予洛伐他汀阻止了治疗后即刻及治疗结束后8周的进一步视网膜神经节细胞丢失和视网膜神经纤维层变薄。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optic gliomas arising in the neurofibromatosis type 1 (NF1) cancer predisposition syndrome cause reduced visual acuity in 30%-50% of affected children. Since human specimens are rare, genetically engineered mouse (GEM) models have been successfully employed for preclinical therapeutic discovery and validation. However, the sequence of cellular and molecular events that culminate in retinal dysfunction and vision loss has not been fully defined relevant to potential neuroprotective treatment strategies. METHODS: Nf1flox/mut GFAP-Cre (FMC) mice and age-matched Nf1flox/flox (FF) controls were euthanized at defined intervals from 2 weeks to 24 weeks of age. Optic nerve volumes were measured, and optic nerves/retinae analyzed by immunohistochemistry. Optical coherence tomography (OCT) was performed on anesthetized mice. FMC mice were treated with lovastatin from 12 to 16 weeks of age. RESULTS: The earliest event in tumorigenesis was a persistent elevation in proliferation (4 wk), which preceded sustained microglia numbers and incremental increases in S100+ glial cells. Microglia activation, as evidenced by increased interleukin (IL)-1β expression and morphologic changes, coincided with axonal injury and retinal ganglion cell (RGC) apoptosis (6 wk). RGC loss and retinal nerve fiber layer (RNFL) thinning then ensued (9 wk), as revealed by direct measurements and live-animal OCT. Lovastatin administration at 12 weeks prevented further RGC loss and RNFL thinning both immediately and 8 weeks after treatment completion. CONCLUSION: By defining the chronology of the cellular and molecular events associated with optic glioma pathogenesis, we demonstrate critical periods for neuroprotective intervention and visual preservation, as well as establish OCT as an accurate biomarker of RGC loss.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Toonen JA, Ma Y, Gutmann DH, et al. Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction. Neuro Oncol. 2017. PMID: 28039362. doi:10.1093/neuonc/now267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。